In a significant update for PaxMedica, Chief Medical Officer David Hough highlighted the company's recent advancements in treating Human African Trypanosomiasis, commonly known as African Sleeping Sickness, during his appearance on The Bell2Bell podcast today. The discussion revolved around the promising outcomes from PaxMedica's PAX-HAT 301 study and other nonclinical programs that have recently been presented to the FDA.
PaxMedica, a biopharmaceutical company focusing on the development of anti-purinergic therapies for neurological disorders, has made substantial progress in its research efforts. Their leading drug candidate, PAX-101, an intravenous suramin formulation, is at the forefront of their work to address conditions such as autism spectrum disorder and African Sleeping Sickness. The FDA's recognition of PaxMedica's comprehensive nonclinical program marks a pivotal moment for the company as it moves closer to a potential treatment for this neglected tropical disease.
The Bell2Bell podcast, produced by InvestorBrandNetwork (IBN), offered a platform for PaxMedica to share these updates. IBN is known for its extensive experience in communications over 17 years and has amassed millions of followers across social media platforms. For further information about PaxMedica's advancements and other news, individuals can access the company's newsroom at PXMD.
The commitment of PaxMedica to combat neglected tropical diseases is further emphasized by their anticipated New Drug Application (NDA) submission slated for 2024. As the company continues its research initiatives focused on meeting the needs of patients with these conditions, this milestone represents a beacon of hope for those affected by African Sleeping Sickness.
InvestorBrandNetwork operates out of Los Angeles with a Corporate Communications department dedicated to client engagement and can be contacted for inquiries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.